Solid lipid nanoparticles are typically spherical with an average diameter between 1 and 1000 nm. It is an alternative carrier system to tradition colloidal carriers, such as, emulsions, liposomes, and polymeric micro and nanoparticles. Recently, solid lipid nanoparticles have received much attention by the researchers owing to its biodegradability, biocompatibility and the ability to deliver a wide range of drugs. The reason for better treatment with SLNs might be the significant uptake of SLNs by due to smaller size and its lipidic nature.

Pravastatin sodium is an cholesteral lowering agent used in the treatment of hyperlipidemia. It is administered through oral route and the dose is 10mg. The oral bioavailability is 17% and half life is 1-3hrs. It is rapidly excreted through the renal route. The aim is to increase the bioavailability of Pravastatin sodium, solid lipid nanoparticles of Pravastatin sodium are prepared by hot homogenization technique using lipids (Trimyristin, Comprital and glyceryl monostearate ) with soylecithin surfactant and poloxamer 188 as stabilizer. The prepared formulations have been evaluated for entrapment efficiency, drug content, in-vitro drug release, particle size analysis, Fourier transform-infrared studies, and stability. The optimization is based upon the range of particle size,zeta potential, and dug release studies. The nanoparticles possess negative surface charge and were enough magnitude for stable preparations. In vitro drug release studies in Phosphate buffer of pH 7.4 exhibited initial burst effect followed by a sustained release of Pravastatin. A solid lipid nanoparticle formulation containing drug pravastatin sodium and lipid Compritol, stabilized with poloxamer 188 as surfactant showed prolonged drug release, smaller particle size, as compared to other formulations with different lipids.